Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?

Tumori

Volumn 96, Issue 5, 2010, Pages 794-795

  Procopio, Giuseppe ^a   Verzoni, Elena ^a   Guadalupi, Valentina ^a   Iacovelli, Roberto ^a   Bajetta, Emilio ^a  

^a NONE

Author keywords

Angiogenesis; Multikinase inhibitors; Renal carcinoma; Targeted therapies; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CEDIRANIB; EVEROLIMUS; PAZOPANIB; RECOMBINANT INTERLEUKIN 2; REGORAFENIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VOLOCIXIMAB;

ANGIOGENESIS; CANCER GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; KIDNEY CARCINOMA; LETTER;

EID: 78650428399     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600528     Document Type: Letter

References (10)

1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Négrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356: 125-134, 2007.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Négrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med, 356: 115-124, 2007. (Pubitemid 46089672)
3. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova B, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial. Lancet, 370: 2103-2111, 2007. (Pubitemid 350296300)
4. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med, 356: 2271-2281, 2007. (Pubitemid 46849157)
5. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald W, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet, 372: 427-429, 2008.
6. Sternberg CN, Szczylik C, Lee E, Salman PV, Mardiak J, Davis ID, Pandite L, Chen M, McCann L, Hawkins R: A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 27: abstr 5021, 2009.
7. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C: Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer, 115: 61-67, 2009.
8. Procopio G, Verzoni E, Guadalupi V, Pietrantonio F, Salvioni R, Nicolai N, Bajetta E: Sequential use of sorafenib (So) followed by Sunitinib (Su) in metastatic renal cell cancer (mRCC). A single-institution experience. Proc ASCO GU, abstr 319, 2009.
9. Sosman JA, Flaherty KT, Atkins MB, McDermott DF, Rothenberg ML, Vermeulen WL, Harlacker K, Hsu A, Wright JJ, Puzanov I: Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol, 26: abstr 5011, 2008.
10. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E: A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin 2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc trial. J Clin Oncol, 27: abstr 5099, 2009.